Breast cancer

Description
Available test Fluorescence in situ hybridisation of FFPE tissue sections for HER2 status
Clinical details
The determination of HER2 status in patients with invasive ductal carcinoma is critical in patient management as it identifies patients who are likely to respond to Herceptin. FISH analysis is used as an adjunctive test in those patients where HER2 immunohistochemistry is borderline, or may also be used as a stand-alone first-line test.
Related condition
Synonyms
HER2, breast cancer, invasive ductal carcinoma, trastuzumab, herceptin
Testing site
Synnovis : Genomics : Guy's Hospital
Laboratory
Oncology Cytogenetics
Sample type and volume required
FFPE tissue sections - 3-4µm sections on unstained Apes slides with accompanying HER2 immunohistochemistry slide for correlation
Turnaround time
Current service turnaround times: 2-7 calendar days; National targets: Urgent samples - 95% reported within 14 days;

Last updated:

Back to search